Study Identifies Cause of Weight Gain From Antipsychotic Drugs

2
From UPI: A team of researchers from the University of Texas Southwestern Medical Center found that the serotonin 2c receptor is responsible for weight gain...

We Need to Talk About Frankie

0
In this piece for The Cut, Dyan Neary details the story of Frankie Perry, a man whose life was forever altered by being prescribed an...

Medical Malpractice Verdict Seen as Powerful Message

1
From PR Newswire: On May 16th, a $2 million verdict was issued in favor of Stanley and Marianne Truskie, whose son died from toxic levels...

The Once and Future Abilify: Depot Injections for Everyone?

23
This column is partly a report on the marketing of Abilify, the atypical antipsychotic that has become America’s best-selling drug.   It’s also an appeal for advice and feedback from the RxISK and Mad in America communities, and a call for some brainstorming about strategy.  The plans laid out by drugmakers Otsuka and Lundbeck for Abilify’s future, and the cooperation they’re getting from leading universities, are alarming enough to me that reporting on them seems inadequate.  We need action, although I’m not sure exactly what kind.

Antipsychotics Increase Mortality Risk in Patients with Parkinson’s Disease

15
A new study in JAMA Neurology finds that the use of antipsychotic drugs more than doubled the risk of death in patients with Parkinson’s...

Call to Monitor Adverse Effects of Antipsychotics in Youth

11
Researchers point to the risks of using antipsychotics with youth and caution against the practice.

One in Seven Scots Take Antidepressants

1
Following a fourfold-increase in antidepressant use in Scotland over the last two decades, one in seven Scots are taking the drugs.  Prescriptions for antipsychotics...

Do Antipsychotics Worsen Long-term Schizophrenia Outcomes? Martin Harrow Explores the Question.

25
Martin Harrow and Thomas Jobe have a new article coming out in Schizophrenia Bulletin that I wish would be read by everyone in our society with an interest in “mental health.” Harrow and Jobe, who conducted the best study of long-term schizophrenia outcomes that has ever been done, do not present new data in this article, but rather discuss the central question raised by their research: Does long-term treatment of schizophrenia with antipsychotic medications facilitate recovery? Or does it hinder it?

“FDA Forced to Release Adverse Event Reports on Psychiatric Drugs”

0
Following a lawsuit brought by Andrew Thibault of Parents Against Pharmaceutical Abuse (PAPA), the FDA has produced adverse event and severe adverse event reports...

Harrow + Wunderink + Open Dialogue = An Evidence-based Mandate for A New Standard...

61
In the wake of the new study by Dutch researcher Lex Wunderink, it is time for psychiatry to do the right thing and acknowledge that, if it wants to do best by its patients, it must change its protocols for using antipsychotics. The current standard of care, which—in practice—involves continual use of antipsychotics for all patients diagnosed with a psychotic disorder, clearly reduces the opportunity for long-term functional recovery.

Antipsychotics for Dementia: Not Justified and Risky

0
In a study of antipsychotics used to treat 75,445 patients in nursing homes in the United States, researchers from Harvard Medical School, Columbia and...

Antipsychotic Drug Associated with Potentially Fatal Skin Rash

5
The US Food and Drug Administration is warning the public that the antipsychotic medication ziprasidone "is associated with a rare but serious skin reaction...

“Direct-to-Consumer Advertising — Selling Drugs or Diseases?”

1
With the American Medical Association (AMA) declaring its opposition to direct-to-consumer (DTC) drug advertising, Martha Rosenberg asks, did DTC increase the number of people who have "diseases"?

Ohio to Review Antipsychotics in Foster and Other Children

0
The state of Ohio plans to invest $1 million in the next three years to review the use of psychiatric drugs prescribed to children,...

The Recovery After an Initial Schizophrenia Episode (RAISE) Study: Notes from the Trenches

43
I was a psychiatrist who participated in the Recovery After an Initial Schizophrenia Episode Early Treatment Program (RAISE ETP). Although I welcomed the positive headlines that heralded the study's results, the reports left me with mixed feelings. What happened to render the notion that talking to people about their experiences and helping them find jobs or go back to school is something novel?

Search Nursing Home Deficiency Reports

0
ProPublica offers an interactive tool that lets you search nursing home inspection reports for problems such as antipsychotic overprescribing.

The History of Whistleblowing, and Whistleblower of the Year

0
1 Boring Old Man reviews the history of whistleblowing, and the story of Allen Jones, who started the ball rolling on the Johnson &...

University of Minnesota Psychiatry: A Pattern of Research Abuse

9
KMSP News has aired a report of yet another mentally ill man pressured to enroll in a study of an unapproved antipsychotic drug, with near-disastrous results. His story bears a striking resemblance to the case of Dan Markingson, who committed suicide in a University of Minnesota study in 2004.

Increase in ED Visits Due to Drug Related Adverse Events

5
A recently published article in the Journal of the American Medical Association highlights an increase in emergency department (ED) visits due to drug-related adverse or negative events.

Relapse in Antipsychotic Drug Trials is Poorly Defined

8
There is a lack of consensus in the definition of ‘relapse’ across randomized controlled trials of antipsychotic maintenance treatment for schizophrenia and psychosis.

When university attorneys play hardball with patients

2
Everyone knows that some attorneys have a reputation for playing hardball.  In fact, many of us even seek out attorneys who play hardball. But...

“Mother’s Little Anti-Psychotic Is Worth $6.9 Billion A Year”

1
In the Daily Beast, Jay Michaelson struggles to make sense of the fact that the antipsychotic Abilify is America's top-selling drug, even while its...

Psychiatry Defends Its Antipsychotics: A Case Study of Institutional Corruption

153
Jeffrey LIeberman and colleagues have published a paper in the American Journal of Psychiatry stating that there is no evidence that psychiatric drugs cause long-term harm, and that the evidence shows that these drugs provide a great benefit to patients. A close examination of their review reveals that it is a classic example of institutional corruption, which was meant to protect guild interests.

AARP Joins Antipsychotic Lawsuit Against CA Nursing Home

2
The AARP has joined an "unprecedented class-action lawsuit" against a California nursing home accused of using antipsychotics without informed consent from residents or family...

J&J Settlement Inspires PA Legislators on False Claims Act

4
Following Johnson & Johnson's $2.2 billion settlement for off-label marketing and kickbacks related to its antipsychotic Risperdal, Pennsylvania legislators Brandon Neuman and Tony DeLuca...